Hormone receptor positive, HER2 negative metastatic breast cancer: future treatment landscape

Redfern, Andrew, Burslem, Katie, Woodward, Natasha, Beith, Jane, McCarthy, Nicole, De Boer, Richard and Bell, Richard (2016) Hormone receptor positive, HER2 negative metastatic breast cancer: future treatment landscape. Asia-Pacific Journal of Clinical Oncology, 12 Supp. 1: 19-31. doi:10.1111/ajco.12492

Author Redfern, Andrew
Burslem, Katie
Woodward, Natasha
Beith, Jane
McCarthy, Nicole
De Boer, Richard
Bell, Richard
Title Hormone receptor positive, HER2 negative metastatic breast cancer: future treatment landscape
Journal name Asia-Pacific Journal of Clinical Oncology   Check publisher's open access policy
ISSN 1743-7563
Publication date 2016-03-01
Year available 2016
Sub-type Article (original research)
DOI 10.1111/ajco.12492
Open Access Status Not Open Access
Volume 12
Issue Supp. 1
Start page 19
End page 31
Total pages 13
Place of publication Chichester, West Sussex United Kingdom
Publisher Wiley-Blackwell Publishing
Collection year 2017
Language eng
Formatted abstract
Endocrine therapy is an established and effective treatment strategy for hormone receptor positive metastatic breast cancer. The clinical utility of endocrine therapy is lost over time due to evolving changes in tumor biology and the development of endocrine resistance.

Many agents targeting the intracellular signaling pathways associated with endocrine resistance are in development. Encouraging early results have been seen for agents which directly target the estrogen receptor (ER), inhibitors of co-signaling pathways, inhibitors of ER chaperones, ER antagonists able to inhibit mutated or otherwise activated ERs, and modulators of histone acetylation restoring synthesis of ER signaling components.

Following our systematic review of treatments with established benefits in this supplement, we review some of the more promising new strategies for overcoming endocrine resistance, looking at the impact on disease control and quality of life for women with hormone receptor positive, HER2 negative breast cancer. We also examine the biomarkers that may guide selection of the best therapy for the individual.
Keyword Breast cancer
Disease-free survival
Hormone receptor positive
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: Mater Research Institute-UQ (MRI-UQ)
HERDC Pre-Audit
Admin Only - School of Medicine
School of Medicine Publications
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 0 times in Thomson Reuters Web of Science Article
Scopus Citation Count Cited 0 times in Scopus Article
Google Scholar Search Google Scholar
Created: Sun, 24 Apr 2016, 00:18:27 EST by System User on behalf of School of Medicine